GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » PensionAndRetirementBenefit

ANL (Adlai Nortye) PensionAndRetirementBenefit : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye PensionAndRetirementBenefit?

Adlai Nortye's PensionAndRetirementBenefit for the quarter that ended in Jun. 2024 was $0.00 Mil.


Adlai Nortye PensionAndRetirementBenefit Historical Data

The historical data trend for Adlai Nortye's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye PensionAndRetirementBenefit Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - -

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
PensionAndRetirementBenefit Get a 7-Day Free Trial - - - - -

Adlai Nortye PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Adlai Nortye Business Description

Industry
Traded in Other Exchanges
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.